{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Zhang S"],"funding":["National Natural Science Foundation of China"],"pubmed_abstract":["<b>Background:</b> Anti-silencing function 1B (ASF1B), a histone H3-H4 chaperone, is crucial for S-phase progression and cell proliferation. Recent studies have shown that ASF1B may be used as a new proliferation marker for cancer prognosis. However, the prognostic value and effect of ASF1B on tumor cells and the immune microenvironment in hepatocellular carcinoma (HCC) remain unclear. <b>Methods:</b> We analyzed the expression of ASF1B and its prognostic value using The Cancer Genome Atlas (TCGA) database (as a training set) and other databases, and we validated the findings by immunohistochemistry in our clinical database, containing 141 HCC patients (as a validation set). Gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA) were performed to probe the tumor-associa"],"journal":["Frontiers in genetics"],"pagination":["842351"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8960381"],"repository":["biostudies-literature"],"pubmed_title":["ASF1B is a Promising Prognostic Biomarker and Correlates With Immunotherapy Efficacy in Hepatocellular Carcinoma."],"pmcid":["PMC8960381"],"pubmed_authors":["Xu L","Li W","Lv K","Jiao M","Hou J","Jiang L","Feng J","Zhu Y","Guo H","Tan D","Wang W","Zhang S"],"additional_accession":[]},"is_claimable":false,"name":"ASF1B is a Promising Prognostic Biomarker and Correlates With Immunotherapy Efficacy in Hepatocellular Carcinoma.","description":"<b>Background:</b> Anti-silencing function 1B (ASF1B), a histone H3-H4 chaperone, is crucial for S-phase progression and cell proliferation. Recent studies have shown that ASF1B may be used as a new proliferation marker for cancer prognosis. However, the prognostic value and effect of ASF1B on tumor cells and the immune microenvironment in hepatocellular carcinoma (HCC) remain unclear. <b>Methods:</b> We analyzed the expression of ASF1B and its prognostic value using The Cancer Genome Atlas (TCGA) database (as a training set) and other databases, and we validated the findings by immunohistochemistry in our clinical database, containing 141 HCC patients (as a validation set). Gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA) were performed to probe the tumor-associa","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-27T01:08:42.183Z","creation":"2025-04-06T18:07:19.283Z"},"accession":"S-EPMC8960381","cross_references":{"pubmed":["35360875"],"doi":["10.3389/fgene.2022.842351"]}}